e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2011
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-34186
(Commission File No.)
|
|
03-0491827
(IRS Employer Identification No.) |
9605 Medical Center Drive
Suite 300
Rockville, Maryland 20850
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (240) 599-4500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item 2.02. |
|
Results of Operations and Financial Condition. |
On February 10, 2011, Vanda Pharmaceuticals Inc. (the Company or Vanda) issued a press
release and is holding a conference call regarding its results of operations and financial
condition for the fourth quarter and year ended December 31, 2010. The full text of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Various statements to be made during the conference call are forward-looking statements
under the securities laws. Words such as, but not limited to, believe, expect, anticipate,
estimate, intend, plan, targets, likely, will, would, and could, and similar
expressions or words, identify forward-looking statements. Forward-looking statements are based
upon current expectations that involve risks, changes in circumstances, assumptions and
uncertainties.
Important factors that could cause actual results to differ materially from those reflected in
the Companys forward-looking statements include, among others: the extent and effectiveness of the
development, sales and marketing and distribution support Fanapt® receives; Vandas ability to
successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of
Vandas clinical trials; a failure of Vandas products to be demonstrably safe and effective;
Vandas failure to obtain regulatory approval for its products or to comply with ongoing regulatory
requirements for its products; a lack of acceptance of Vandas products in the marketplace, or a
failure to become or remain profitable; Vandas expectations regarding trends with respect to its
costs and expenses; Vandas inability to obtain the capital necessary to fund additional research
and development activities; Vandas failure to identify or obtain rights to new products; Vandas
failure to develop or obtain sales, marketing and distribution resources and expertise or to
otherwise manage its growth; a loss of any of Vandas key scientists or management personnel;
losses incurred from product liability claims made against Vanda; a loss of rights to develop and
commercialize Vandas products under its license and sublicense agreements and other factors that
are described in the Risk Factors and Managements Discussion and Analysis of Financial
Condition and Results of Operations sections of Vandas Annual Report on Form 10-K for the fiscal
year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2010, which are on file with the SEC and available on the SEC website at www.sec.gov.
Additional information will also be set forth in those sections of Vandas Annual Report on Form
10-K for the fiscal year ended December 31, 2010, which will be filed with the SEC in the first
quarter of 2011. In addition to the risks described above and in Vandas Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, other unknown or unpredictable factors also could affect
Vandas results. There can be no assurance that the actual results or developments anticipated by
Vanda will be realized or, even if substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting
on its behalf are expressly qualified in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking
statements Vanda makes or that are made on its behalf. The information conveyed on the conference
call will be provided only as of the date of the call, and the Company undertakes no obligation,
and specifically declines any obligation, to update or revise publicly any forward-looking
statements made during the call after the date thereof, whether as a result of new information,
future events, or otherwise.
The information in Item 2.02 of this Current Report on Form 8-K and the Exhibit attached
hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
|
|
Item 9.01. |
|
Financial Statements and Exhibits. |
|
|
|
|
|
Exhibit No. |
|
Description |
|
99.1 |
|
|
Press release of Vanda Pharmaceuticals Inc. dated February 10, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
VANDA PHARMACEUTICALS INC.
|
|
|
By: |
/s/ James Kelly
|
|
|
|
Name: |
James Kelly |
|
|
|
Title: |
Chief Financial Officer |
|
|
Dated: February 10, 2011
exv99w1
Exhibit 99.1
Company Contact:
Cristina Murphy
Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
cristina.murphy@vandapharma.com
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
ROCKVILLE, MD. February 10, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:
VNDA), a biopharmaceutical company focused on the development and commercialization of
products for central nervous system disorders, today announced financial and operational results
for the fourth quarter and full year ended December 31, 2010.
2010 has been an exceptional milestone year in the history of our company. Our first product,
Fanapt®, reached the U.S. market for the treatment of schizophrenia, we had our first profitable
year and we have advanced our second asset, tasimelteon, in Phase 3 studies, said Mihael
Polymeropoulos, M.D., President and Chief Executive Officer. 2011 will be a foundation year for
Vanda, as we begin to execute upon our vision of building a world class neuroscience pharmaceutical
company.
Key Highlights:
|
|
|
Vanda recorded 2010 revenue of $35.2 million including royalties and product sales of
$8.4 million. |
|
|
|
|
Cash and cash equivalents plus marketable securities at year end 2010 were $198.0
million as compared to $205.3 million at year end 2009. |
|
|
|
|
Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in
September of 2010 to over 8,000 in December of 2010. For the full year 2010, more than
55,000 prescriptions were written. |
|
|
|
|
Tasimelteon efficacy and safety studies are ongoing in both the U.S. and Europe. |
|
|
|
|
On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal
Revenue Service (IRS) clarifying the companys ability to utilize net operating loss
carryforwards for tax purposes. |
Page 1 of 9
Full Year 2010 Reported Results
Total revenues for the full year 2010 were $35.2 million, compared to $4.5 million for the same
period in 2009. 2010 revenues included $26.8 million recognized from the $200.0 million upfront
payment previously received from Novartis for
Fanapt® U.S. and Canadian rights. Total operating
expenses for 2010 were $26.9 million, compared to $40.5 million for 2009. The lower 2010 spend is
primarily related to decreased business development consulting fees and lower non-cash stock based
compensation for the period.
Net income was $7.2 million for 2010, compared to a net loss of $35.9 million for 2009. Diluted
earnings per share for 2010 was $0.25, compared to a net loss per share of $1.33 for 2009. Vandas
cash, cash equivalents, and marketable securities as of December 31, 2010 totaled $198.0 million.
Fourth Quarter 2010 Reported Results
Total revenues for the fourth quarter of 2010 were $7.3 million, compared to $4.5 million for the
same period in 2009. Fourth quarter 2010 revenues include $0.5 million related to Fanapt®
royalties received from Novartis. Total operating expenses for the fourth quarter of 2010 were
$7.0 million, compared $13.8 million for the fourth quarter of 2009. The primary drivers of the
lower 2010 spend were the one time nature of Fanapt® product cost of goods sold in 2009 and the
previously mentioned decrease in business development expenses.
Net income was $2.2 million for the fourth quarter of 2010, compared to a net loss of $9.2 million
for the fourth quarter of 2009. Diluted earnings per share for the fourth quarter of 2010 was
$0.08, compared a net loss per share of $0.34 for the fourth quarter of 2009.
Full Year December 31, 2010 Key Financial Figures1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
|
|
|
|
|
December 31 |
|
December 31 |
|
|
|
|
(in thousands, except per share amounts) |
|
2010 |
|
2009 |
|
Change ($) |
|
Change (%) |
Total revenues |
|
$ |
35,220 |
|
|
$ |
4,548 |
|
|
$ |
30,672 |
|
|
|
674 |
% |
Research & development expenses |
|
|
12,338 |
|
|
|
13,874 |
|
|
|
(1,536 |
) |
|
|
-11 |
% |
General & administrative expenses |
|
|
10,147 |
|
|
|
23,724 |
|
|
|
(13,577 |
) |
|
|
-57 |
% |
Non-cash stock-based compensation |
|
|
4,981 |
|
|
|
11,230 |
|
|
|
(6,249 |
) |
|
|
-56 |
% |
Net income (loss) before tax provision |
|
|
9,269 |
|
|
|
(35,859 |
) |
|
|
45,128 |
|
|
|
126 |
% |
Tax provision |
|
|
2,077 |
|
|
|
|
|
|
|
2,077 |
|
|
NA |
Net income (loss) |
|
|
7,192 |
|
|
|
(35,859 |
) |
|
|
43,051 |
|
|
|
120 |
% |
Diluted net income (loss) per share |
|
$ |
0.25 |
|
|
$ |
(1.33 |
) |
|
$ |
1.58 |
|
|
|
119 |
% |
Fourth Quarter 2010 Key Financial Figures1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
December 31 |
|
September 30 |
|
|
|
|
(in thousands, except per share amounts) |
|
2010 |
|
2010 |
|
Change ($) |
|
Change (%) |
Total revenues |
|
$ |
7,263 |
|
|
$ |
7,246 |
|
|
$ |
17 |
|
|
|
0 |
% |
Research & development expenses |
|
|
3,822 |
|
|
|
4,072 |
|
|
|
(250 |
) |
|
|
-6 |
% |
General & administrative expenses |
|
|
2,762 |
|
|
|
2,054 |
|
|
|
708 |
|
|
|
34 |
% |
Non-cash stock-based compensation |
|
|
1,335 |
|
|
|
887 |
|
|
|
448 |
|
|
|
51 |
% |
Net income before tax provision |
|
|
933 |
|
|
|
899 |
|
|
|
34 |
|
|
|
4 |
% |
Tax benefit |
|
|
(1,266 |
) |
|
|
(2,285 |
) |
|
|
1,019 |
|
|
|
45 |
% |
Net income |
|
|
2,199 |
|
|
|
3,184 |
|
|
|
(985 |
) |
|
|
-31 |
% |
Diluted net income per share |
|
$ |
0.08 |
|
|
$ |
0.11 |
|
|
$ |
(0.03 |
) |
|
|
-27 |
% |
Page 2 of 9
Select Balance Sheet Data1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31 |
|
September 30 |
|
December 31 |
(in thousands, except per share amounts) |
|
2010 |
|
2010 |
|
2009 |
Total cash and marketable securities |
|
$ |
198,037 |
|
|
$ |
202,060 |
|
|
$ |
205,295 |
|
1 Unaudited
OPERATIONAL HIGHLIGHTS
Full year 2010 sales of Fanapt® were reported by Novartis to be $31.4 million which included $5.1
million in the fourth quarter of 2010. Vanda is encouraged by the continuing growth in the total
number of monthly prescriptions, as reported by IMS. Fanapt® prescriptions continued to increase
month-over-month during the fourth quarter of 2010. Monthly prescriptions of Fanapt®, as reported
by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010. For the
full year 2010, more than 55,000 prescriptions were written.
We have been informed by our partner, Novartis, that a clinical study will be initiated in early
2011 for the once a month injectable depot formulation of iloperidone. On October 28, 2010, the
U.S. Patent and Trademark Office (USPTO) informed Vanda that it had granted an additional patent
term adjustment for the depot formulation, making the patent expiration date August 25, 2023.
Vanda continues to explore the regulatory path and commercial opportunity for the Fanapt® oral
formulation outside of the U.S. and Canada. On November 1, 2010, Australias Department of Health
and Ageing Therapeutic Goods Administration, accepted for evaluation Vandas application for
marketing approval.
Enrollment is ongoing in the tasimelteon Study VP-VEC-162-3201, a 160-patient randomized controlled
trial of tasimelteon versus placebo in the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD)
in blind individuals with no light perception. The trial has a 6-month treatment period and
includes measures of both nighttime and daytime sleep, as well as laboratory measures of the
synchronization between the internal body clock and the 24-hour environmental light/dark cycle.
Vanda has also initiated a one-year safety study of tasimelteon for the treatment of N24HSWD. This
is an open-label safety study that will enroll approximately 140 patients with N24HSWD. Vanda
plans to conduct additional clinical trials over the next one to two years to support U.S. and
European regulatory submissions. Tasimelteon was granted orphan drug designation by the FDA on
January 19, 2010. On November 12, 2010, the Committee for Orphan Medicinal Products (COMP) of the
European Medicines Agency (EMA) issued a positive opinion on the application for orphan drug
designation for tasimelteon. A final decision on the application for orphan designation from the
EMA is pending.
On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue
Service (IRS) regarding certain income tax issues associated with the availability of Vandas net
operating loss carryforwards for tax purposes. The PLR is generally consistent with Vandas stated
tax position that it is able to offset a portion of its 2010 taxable income with the companys full
net operating loss carryforwards. Total net operating loss carryforwards were $123 million as of
December 31, 2008. As of December 31, 2009, total net operating loss carryforwards were $156
million. Vanda believes that the PLR received from the IRS clarifies certain tax rules regarding
the use of these net operating loss carryforwards and will support Vandas position
that its December 31, 2009 net operating loss carryforwards can be fully utilized
beginning in 2010.
Page 3 of 9
2011 FINANCIAL GUIDANCE
|
|
General and administrative expenses are expected to be between $10.0 and $12.0 million.
This is consistent with the 2010 general and administrative expense of $10.1 million. |
|
|
|
Research and development expenses are expected to be between $26.0 and $29.0 million. This
represents a $14.0 to $17.0 million increase over 2010 and reflects our investment in the
Phase 3 development of tasimelteon in N24HSWD. This is consistent with our prior guidance
that we expect to spend between $30.0 and $35.0 million in total to file an NDA. |
|
|
|
Total GAAP operating expenses are expected to be between $37.0 and $42.0 million. This
includes Fanapt® cost of sales of $1.5 million related to amortization of an intangible asset
and $5.0 to $6.0 million of stock-based compensation. |
CONFERENCE CALL
Vanda has scheduled a conference call for today, Thursday, February 10, 2011, at 10:00 AM ET.
During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and James Kelly, Senior Vice
President and Chief Financial Officer, will discuss quarterly results and other corporate
activities. Investors can call 1-800-591-6942 (domestic) and 1-617-614-4909 (international) prior
to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr.
Polymeropoulos (participant passcode 43128562). A replay of the call will be available Thursday,
February 10, 2011 at 1:00 PM ET and will be accessible until Thursday, February 17, 2010, at 5:00
PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for
international callers. The access number is 66575807.
The conference call will be broadcast simultaneously on Vandas website,
http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised
to go to the website at least 15 minutes early to register, download, and install any necessary
software or presentations. The call will also be archived on Vandas website for a period of 30
days, through March 12, 2011.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and
commercialization of products for central nervous system disorders. For more on Vanda, please
visit http://www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are forward-looking statements under the securities laws.
Words such as, but not limited to, believe, expect, anticipate, estimate, intend, plan,
targets, likely, will, would, and could, and similar expressions or words, identify
forward-looking statements. Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and uncertainties. Important factors that
could cause actual results to differ materially from those reflected in the companys
forward-looking statements include, among others: the extent and effectiveness of the development,
sales and marketing and distribution support Fanapt® receives; Vandas ability to successfully
commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vandas clinical
trials; a failure of Vandas products to be demonstrably safe and effective; Vandas failure to
obtain regulatory approval for its products or to comply with ongoing regulatory requirements for
its products; a lack of acceptance of Vandas products in the marketplace, or a failure to become
or remain profitable; Vandas expectations regarding trends with respect to its costs and expenses;
Vandas inability to obtain the capital necessary to fund additional research and development
activities; Vandas failure to identify or obtain rights to new products; Vandas
failure to develop or obtain sales, marketing and distribution resources and expertise or to
otherwise manage its growth; a loss of any of Vandas key scientists or management personnel;
Page 4 of 9
losses incurred from product liability claims made against Vanda; a loss of rights to develop and
commercialize Vandas products under its license and sublicense agreements and other factors that
are described in the Risk Factors and Managements Discussion and Analysis of Financial
Condition and Results of Operations sections of Vandas annual report on Form 10-K for the fiscal
year ended December 31, 2009 and quarterly report on Form 10-Q for the fiscal quarter ended
September 30, 2010, which are on file with the SEC and available on the SECs website at
www.sec.gov. Additional information will also be set forth in those sections of Vandas annual
report on Form 10-K for the fiscal year ended December 31, 2010, which will be filed with the SEC
in the first quarter of 2011. In addition to the risks described above and in Vandas annual report
on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could
affect Vandas results. There can be no assurance that the actual results or developments
anticipated by Vanda will be realized or, even if substantially realized, that they will have the
expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the
outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its
behalf are expressly qualified in their entirety by the cautionary statements contained or referred
to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda
makes or that are made on its behalf. The information in this release is provided only as of the
date of this release, and Vanda undertakes no obligation, and specifically declines any obligation,
to update or revise publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
####
Page 5 of 9
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
December 31, |
|
|
December 31, |
|
(In thousands, except for per share amounts) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing agreement |
|
$ |
6,752 |
|
|
$ |
2,569 |
|
|
$ |
26,789 |
|
|
$ |
2,569 |
|
Royalty revenue |
|
|
511 |
|
|
|
|
|
|
|
3,141 |
|
|
|
|
|
Product sales |
|
|
|
|
|
|
1,979 |
|
|
|
5,290 |
|
|
|
1,979 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
7,263 |
|
|
|
4,548 |
|
|
|
35,220 |
|
|
|
4,548 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales licensing agreement |
|
|
377 |
|
|
|
377 |
|
|
|
1,495 |
|
|
|
983 |
|
Cost of sales product |
|
|
|
|
|
|
1,915 |
|
|
|
2,891 |
|
|
|
1,915 |
|
Research and development |
|
|
3,822 |
|
|
|
2,253 |
|
|
|
12,338 |
|
|
|
13,874 |
|
General and administrative |
|
|
2,762 |
|
|
|
9,245 |
|
|
|
10,147 |
|
|
|
23,724 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
6,961 |
|
|
|
13,790 |
|
|
|
26,871 |
|
|
|
40,496 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
|
302 |
|
|
|
(9,242 |
) |
|
|
8,349 |
|
|
|
(35,948 |
) |
Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
142 |
|
|
|
5 |
|
|
|
431 |
|
|
|
89 |
|
Grant income |
|
|
489 |
|
|
|
|
|
|
|
489 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income |
|
|
631 |
|
|
|
5 |
|
|
|
920 |
|
|
|
89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax provision |
|
|
933 |
|
|
|
(9,237 |
) |
|
|
9,269 |
|
|
|
(35,859 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax provision (benefit) |
|
|
(1,266 |
) |
|
|
|
|
|
|
2,077 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
2,199 |
|
|
$ |
(9,237 |
) |
|
$ |
7,192 |
|
|
$ |
(35,859 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.08 |
|
|
$ |
(0.34 |
) |
|
$ |
0.26 |
|
|
$ |
(1.33 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
$ |
0.08 |
|
|
$ |
(0.34 |
) |
|
$ |
0.25 |
|
|
$ |
(1.33 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in calculation of net income
(loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
28,038,074 |
|
|
|
27,286,667 |
|
|
|
27,916,388 |
|
|
|
27,015,271 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
28,892,347 |
|
|
|
27,286,667 |
|
|
|
28,534,617 |
|
|
|
27,015,271 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 6 of 9
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
|
|
|
|
|
|
|
|
|
(In thousands, except for per share amounts) |
|
December 31, 2010 |
|
|
December 31, 2009 |
|
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
42,559 |
|
|
$ |
205,295 |
|
Marketable securities |
|
|
155,478 |
|
|
|
|
|
Accounts receivable |
|
|
511 |
|
|
|
3,164 |
|
Inventory |
|
|
|
|
|
|
2,399 |
|
Prepaid expenses, deposits and other current assets |
|
|
1,843 |
|
|
|
2,093 |
|
Deferred tax, current |
|
|
1,821 |
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
202,212 |
|
|
|
212,951 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
937 |
|
|
|
1,316 |
|
Restricted cash |
|
|
430 |
|
|
|
430 |
|
Intangible asset, net |
|
|
9,522 |
|
|
|
11,017 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
213,101 |
|
|
$ |
225,714 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
649 |
|
|
$ |
2,424 |
|
Accrued expenses |
|
|
1,324 |
|
|
|
2,321 |
|
Accrued income taxes |
|
|
2,266 |
|
|
|
|
|
Deferred revenue, current |
|
|
26,789 |
|
|
|
26,789 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
31,028 |
|
|
|
31,534 |
|
|
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
Deferred rent |
|
|
490 |
|
|
|
507 |
|
Deferred revenue, non-current |
|
|
143,853 |
|
|
|
170,642 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
175,371 |
|
|
|
202,683 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
28 |
|
|
|
28 |
|
Additional paid-in capital |
|
|
291,342 |
|
|
|
283,836 |
|
Accumulated other comprehensive income |
|
|
2 |
|
|
|
|
|
Accumulated deficit |
|
|
(253,642 |
) |
|
|
(260,833 |
) |
|
|
|
|
|
|
|
Total stockholders equity |
|
|
37,730 |
|
|
|
23,031 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
213,101 |
|
|
$ |
225,714 |
|
|
|
|
|
|
|
|
Page 7 of 9
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
|
|
December 31, |
|
|
December 31, |
|
(In thousands, except for per share amounts) |
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
7,192 |
|
|
$ |
(35,859 |
) |
Adjustments to reconcile net income (loss) to net cash used
in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
336 |
|
|
|
442 |
|
Stock-based compensation |
|
|
4,981 |
|
|
|
11,230 |
|
Loss on disposal of assets |
|
|
(23 |
) |
|
|
|
|
Amortization of premium/discounts on investments |
|
|
212 |
|
|
|
138 |
|
Amortization of intangible assets |
|
|
1,495 |
|
|
|
983 |
|
Deferred tax benefit |
|
|
(1,821 |
) |
|
|
|
|
Excess tax benefits from exercise of stock options |
|
|
(2,892 |
) |
|
|
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
250 |
|
|
|
(805 |
) |
Accounts receivable |
|
|
2,653 |
|
|
|
(3,164 |
) |
Inventory |
|
|
2,399 |
|
|
|
(2,398 |
) |
Accounts payable |
|
|
(1,775 |
) |
|
|
1,911 |
|
Accrued expenses |
|
|
(997 |
) |
|
|
(577 |
) |
Accrued income taxes |
|
|
3,898 |
|
|
|
|
|
Other liabilities |
|
|
(17 |
) |
|
|
4 |
|
Deferred revenue |
|
|
(26,789 |
) |
|
|
197,431 |
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities |
|
|
(10,898 |
) |
|
|
169,336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Acquisition of intangible asset |
|
|
|
|
|
|
(12,000 |
) |
Proceeds from sales of property and equipment |
|
|
66 |
|
|
|
|
|
Purchases of investments |
|
|
(202,438 |
) |
|
|
(11,366 |
) |
Proceeds from sales of investments |
|
|
|
|
|
|
127 |
|
Proceeds from maturities of investments |
|
|
46,750 |
|
|
|
18,500 |
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(155,622 |
) |
|
|
(4,739 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Excess tax benefits from exercise of stock options |
|
|
2,892 |
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
892 |
|
|
|
1,619 |
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
3,784 |
|
|
|
1,619 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
(162,736 |
) |
|
|
166,216 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of period |
|
|
205,295 |
|
|
|
39,079 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
|
$ |
42,559 |
|
|
$ |
205,295 |
|
|
|
|
|
|
|
|
Page 8 of 9
SOURCE Vanda Pharmaceuticals Inc.
CONTACT: Cristina Murphy, Communications Manager, of Vanda Pharmaceuticals Inc., +1-240-599-4500
Web site: http://www.vandapharma.com
(VNDA)
CO: Vanda Pharmaceuticals Inc.
Page 9 of 9